MESOBLAST LTD
MEOBF$1.74B
Small CapNASDAQBiotechnology🇺🇸North America81 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
MEOBF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Prochymal®
Graft Versus Host Disease
Remestemcel-L
Grade B Acute Graft Versus Host Disease
Mesenchymal Precursor Cells (MPCs)
Heart Failure
NeoFuse
Degenerative Disc Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Prochymal® | Phase 3 | Graft Versus Host Disease | - | - |
Remestemcel-L | Phase 3 | Grade B Acute Graft Versus Host Disease | - | - |
Mesenchymal Precursor Cells (MPCs) | Phase 2 | Heart Failure | - | - |
NeoFuse | Phase 2 | Degenerative Disc Disease | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply